Project

OPEN TrialChain

Groups

In this project, we are motivated to address clinical trials issues using Blockchain technology. We propose, OPEN TrialChain, a privacy-preserving Blockchain-based data sharing infrastructure that uses open algorithms between stakeholder of the federation in the clinical trials ecosystem. OPEN TrialChain balances between the sharing of clinical data and the need for subject’s privacy protection by allowing queries on decentralized raw datasets from which it returns aggregated safe answers that are blinded (i.e. anonymized). Using Type II Diabetes as a case study, we study the adoption of OPEN TrialChain and how it can address clinical trials issues. Results show that OPEN TrialChain, first, encourages pharmaceutical companies to report their trial results with higher fidelity, as well as, federated ones to provide more detailed results in return for their peers’ detailed results. Furthermore, it allows for multiple studies to be queried for results from underrepresented demographics, producing greater insight from previously ignored minorities. Finally, analysis done using OPEN TrialChain should illustrate meaningful r… View full description

In this project, we are motivated to address clinical trials issues using Blockchain technology. We propose, OPEN TrialChain, a privacy-preserving Blockchain-based data sharing infrastructure that uses open algorithms between stakeholder of the federation in the clinical trials ecosystem. OPEN TrialChain balances between the sharing of clinical data and the need for subject’s privacy protection by allowing queries on decentralized raw datasets from which it returns aggregated safe answers that are blinded (i.e. anonymized). Using Type II Diabetes as a case study, we study the adoption of OPEN TrialChain and how it can address clinical trials issues. Results show that OPEN TrialChain, first, encourages pharmaceutical companies to report their trial results with higher fidelity, as well as, federated ones to provide more detailed results in return for their peers’ detailed results. Furthermore, it allows for multiple studies to be queried for results from underrepresented demographics, producing greater insight from previously ignored minorities. Finally, analysis done using OPEN TrialChain should illustrate meaningful results without violating the privacy of individuals. Eventually, OPEN TrialChain is expected to optimize the clinical trial ecosystem by improving patient safety, saving lives, cutting drug development costs, encouraging transparent results, preserving patients privacy, and maintaining pharmaceuticals integrity.

Copyright

Shada Alsalamah and Anne Kim